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UCHL1 provides diagnostic and antimetastatic
strategies due to its deubiquitinating effect
on HIF-1a
Yoko Goto1,2, Lihua Zeng1,2,3, Chan Joo Yeom1,2, Yuxi Zhu1,2,4, Akiyo Morinibu1,2, Kazumi Shinomiya1,2,
Minoru Kobayashi1,2, Kiichi Hirota5, Satoshi Itasaka1, Michio Yoshimura1, Keiji Tanimoto6, Masae Torii7,
Terumasa Sowa8, Toshi Menju8, Makoto Sonobe8, Hideaki Kakeya9, Masakazu Toi7, Hiroshi Date8,
Ester M. Hammond10, Masahiro Hiraoka1 & Hiroshi Harada1,2,11
Hypoxia-inducible factor 1 (HIF-1) plays a role in tumour metastases; however, the genes that
activate HIF-1 and subsequently promote metastases have yet to be identiﬁed. Here we show
that Ubiquitin C-terminal hydrolase-L1 (UCHL1) abrogates the von Hippel–Lindau-mediated
ubiquitination of HIF-1a, the regulatory subunit of HIF-1, and consequently promotes
metastasis. The aberrant overexpression of UCHL1 facilitates distant tumour metastases in a
HIF-1-dependent manner in murine models of pulmonary metastasis. Meanwhile, blockade of
the UCHL1–HIF-1 axis suppresses the formation of metastatic tumours. The expression levels
of UCHL1 correlate with those of HIF-1a and are strongly associated with the poor prognosis
of breast and lung cancer patients. These results indicate that UCHL1 promotes metastases
as a deubiquitinating enzyme for HIF-1a, which justiﬁes exploiting it as a prognostic marker
and therapeutic target of cancers.
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M
etastasis is the major cause of death among cancer
patients1. Previous studies have shown that hypoxia-
inducible factor 1 (HIF-1) plays important roles in
distant tumour metastases at multiple steps2,3. Clinical studies
have also demonstrated that HIF-1 could be used as an adverse
prognostic factor for both local tumour recurrence and distant
tumour metastasis in cancer patients4,5. These ﬁndings have
justiﬁed targeting HIF-1 for cancer therapies6,7.
HIF-1 is a heterodimer composed of an a-subunit (HIF-1a)
and b-subunit (HIF-1b), and its activity is mainly regulated
through oxygen-dependent changes in protein stability and the
transactivation activity of HIF-1a6,7. Under normoxic conditions,
prolyl-4-hydroxylases hydroxylate the proline residues, P402 and
P564, in the oxygen-dependent degradation (ODD) domain of
HIF-1a8,9. This hydroxylation triggers ubiquitination by a von
Hippel–Lindau (VHL)-containing E3 ubiquitin ligase, which
leads to the rapid proteolysis of HIF-1a8,9. In addition, the
asparagynyl-hydroxylase, factor inhibiting HIF-1, hydroxylates
the asparagine residue, N803, in the C-terminal transactivation
domain of HIF-1a, resulting in the suppression of its
transactivation activity10,11. In contrast, HIF-1a becomes stable
and active under hypoxic conditions because of the inactivation
of oxygen-dependent hydoxylases8,9. The resulting heterodimer,
HIF-1, binds to its cognate enhancer sequence, the hypoxia
response element (HRE), and induces the expression of various
genes responsible for distant tumour metastases, angiogenesis and
metabolic reprogramming3,6,7. Thus, the mechanism by which
HIF-1 activity is inﬂuenced by oxygen availability has been
characterized in detail; however, the genes that actively induce
HIF-1 activity and consequently promote metastases remain
largely unknown. Elucidating this molecular network, especially
identifying the novel upstream activators of HIF-1, may provide a
valuable insight that could eradicate secondary cancers because
they can be exploited as targets for cancer therapy.
In the present study, we provided a novel insight into the
regulatory mechanism underlying tumour metastasis via activa-
tion of the Ubiquitin C-terminal hydrolase-L1 (UCHL1)-HIF-1
pathway. We successfully identiﬁed UCHL1 as a novel upstream
activator of HIF-1 through an original genetic screening strategy.
The aberrant expression of UCHL1 was shown to promote
distant tumour metastasis via the activation of HIF-1. Loss-of-
function studies and an inhibitor for UCHL1 conﬁrmed the
importance of UCHL1 for cancer therapy. Moreover, expression
levels of UCHL1 in breast and lung cancers were found to be
associated with those of HIF-1a and poor prognosis in cancer
patients.
Results
UCHL1 upregulates HIF-1 activity. We developed a new genetic
screening method to explore the novel activators of HIF-1 with
the expectation that they would include a prometastatic factor.
Using an artiﬁcial promoter composed of ﬁve repeats of the HRE
and the human cytomegalovirus (CMV) minimal promoter
(5HRE promoter: herein designated as 5HREp)12,13, we
constructed a p5HREp-bsd plasmid that expressed the
blasticidin S-resistant gene (bsd) in a HIF-1-dependent manner
(Supplementary Fig. 1a). The stable transfectant of NIH3T3 cells
with p5HREp-bsd (NIH3T3/5HREp-bsd) was sensitive to
blasticidin S under normoxic conditions because of its
insufﬁcient expression of both HIF-1a and BSD
(Supplementary Fig. 1b). After introducing the human
complementary DNA library, NIH3T3/5HREp-bsd cells were
cultured in blasticidin S-containing medium under normoxic
conditions as the resultant surviving colonies were expected to be
introduced with cDNAs encoding an activator of HIF-1. We
isolated several surviving colonies through this gene screening
approach, and identiﬁed UCHL1 as a candidate for a novel
upstream activator of HIF-1 by further analysing one of the
surviving colonies.
We performed a luciferase assay using the 5HREp-luc reporter
gene, which expressed ﬁreﬂy luciferase under the control of
5HREp12,14, to examine whether UCHL1 induced HIF-1 activity.
The forced expression of UCHL1 in cervical and breast cancer cell
lines that originally showed no detectable expression of
endogenous UCHL1 resulted in the upregulation of 5HREp-luc
reporter activity under both normoxic and hypoxic conditions
(Fig. 1a,b and Supplementary Figs 2 and 3). On the other hand,
the knockdown of robust endogenous UCHL1 expression
(Supplementary Figs 2,4) resulted in the signiﬁcant suppression
of 5HREp-luc reporter activity independently of the oxygen
conditions (Fig. 1c and Supplementary Fig. 5). The positive
impact of UCHL1 on 5HREp-luc reporter activity was almost
completely abrogated by the short interfering RNA (siRNA)
treatment against the HIF-1a gene (Supplementary Fig. 6).
Quantitative reverse transcription PCR (qRT–PCR) analyses
for VEGF, GLUT1 and MMP9 demonstrated that the forced
expression and knockdown of UCHL1 resulted in the signi-
ﬁcant induction of and reduction in the expression of HIF-1-
downstream genes, respectively (Fig. 1d,e and Supplementary
Figs 4 and 7). These results clearly indicated that UCHL1
upregulated HIF-1 activity in various cancer cell lines.
UCHL1 increases the stability of HIF-1a. We then examined the
molecular mechanisms underlying the upregulation of HIF-1 by
UCHL1. UCHL1 was previously reported to function as a deu-
biquitinating enzyme15; therefore, we assumed that it would
recognize HIF-1a as a substrate and increase its stability in cancer
cells. As hypothesized, immunoblotting clearly demonstrated that
the expression of the HIF-1a protein was signiﬁcantly increased
after the overexpression of UCHL1 under hypoxic conditions
(Fig. 2a). However, it was difﬁcult to observe an increase in this
protein under normoxic conditions as basal HIF-1a expression
levels were below detectable levels in this experimental condition
(Fig. 2a). The induction of HIF-1a protein expression under low-
oxygen conditions was signiﬁcantly decreased when cells were
treated with siRNA against the endogenous UCHL1 gene (Fig. 2b
and Supplementary Fig. 4). To further determine whether UCHL1
inﬂuenced the stability of the HIF-1a protein, we used the SV40p-
ODD-luc reporter gene, which emits luciferase bioluminescence
under the same regulation as HIF-1a stability because of the fusion
of luciferase to the ODD domain (HIF-1a 548–604 amino acid
(a.a.))16. The reporter assay demonstrated that the overexpression
and knockdown of UCHL1 signiﬁcantly increased and decreased
ODD-Luc fusion protein levels, respectively (Fig. 2c,d and Supple-
mentary Fig. 4). Moreover, the forced expression of UCHL1
prolonged the half-life of the fusion protein following reoxygena-
tion (Supplementary Fig. 8). Western blotting demonstrated that
UCHL1 functioned not only in stabilizing the HIF-1a protein
following the reoxygenation treatment (Fig. 2e), but also in the
accelerated accumulation of HIF-1a after the availability of oxygen
decreased (Fig. 2f). These results collectively indicated that UCHL1
positively inﬂuenced the stability of the HIF-1a protein.
UCHL1 functions as a deubiquitinating enzyme for HIF-1a.
We then investigated whether the deubiquitinating activity of
UCHL1 played an important role in increasing the stability of
HIF-1a and activity of HIF-1. We constructed a plasmid
expressing the catalytically inactive mutant form of UCHL1, in
which a cysteine residue, C90, was substituted for serine. The
C90S mutation abrogated the UCHL1-mediated increase in both
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5HREp-luc and SV40p-ODD-luc reporter activities under nor-
moxic and hypoxic conditions (Fig. 3a,b). Moreover, when the
ubiquitination status of the HIF-1a protein was directly evaluated
by performing immunoprecipitation assays, the knockdown of
endogenous UCHL1 signiﬁcantly increased HIF-1a ubiquitina-
tion (Fig. 3c and Supplementary Fig. 9). On the other hand, the
overexpression of UCHL1 resulted in a decrease in HIF-1a ubi-
quitination (Fig. 3d). The deubiquitinating effect on HIF-1a
appeared to have been achieved by a direct interaction between
UCHL1 and HIF-1a (Fig. 3e). Moreover, this interaction was
conﬁrmed to prevent VHL from directly interacting
with HIF-1a (Fig. 3f). Furthermore, luciferase assays using the
5HREp-luc reporter gene demonstrated that the overexpression
of UCHL1 had no impact on HIF-1 activity in VHL-defective
RCC4 cells (RCC4 plus vector alone; Fig. 3g, left), but had a
positive inﬂuence in VHL-reconstituted RCC4 cells (RCC4
plus VHL; Fig. 3g, right). Western blotting consistently showed
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Figure 1 | UCHL1 upregulates HIF-1 activity. (a,b) HeLa/5HRE-Luc (a) and MCF7/5HRE-Luc (b) cells were transfected with pcDNA4/UCHL1 (UCHL1) or
pcDNA4/myc-His A (empty vector: EV), cultured under normoxic (20%) or hypoxic (1%) conditions for the indicated period, and subjected to the
luciferase assay and western blotting using the indicated antibodies. (c) 293T (left) and MDA-MB-436 (right) cells transiently transfected with p5HREp-
Luc were treated with scramble-siRNA (Scr) or UCHL1-siRNA (siUCHL1), cultured under normoxic (20%) or hypoxic (1%) conditions for 24 h, and
subjected to the luciferase assay. (d,e) HeLa (d) and 293T (e) cells were transiently transfected with either pcDNA4/UCHL1 (UCHL1) or pcDNA4/myc-
His A (EV) (d) or treated with either scramble-siRNA (Scr) or UCHL1-siRNA (siUCHL1) (e), cultured under normoxic (20%) or hypoxic (1%) conditions for
24 h, and then subjected to western blotting using the indicated antibodies and qRT–PCR to quantify the mRNA levels of the indicated genes. Mean±s.d.
n¼ 3. *Po0.05, **Po0.01, Student’s t-test (a,b,d) and Dunnett’s test (c,e).
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Figure 2 | UCHL1 increases the stability of HIF-1a. (a,b) HeLa (a) and 293T (b) cells were transiently transfected with either pcDNA4/UCHL1 (UCHL1) or
pcDNA4/myc-His A (EV) (a) or treated with either scramble-siRNA (Scr) or UCHL1-siRNA (siUCHL1) (b), cultured under normoxic (20%) or hypoxic
(0.1%) conditions for 24 h, and then subjected to western blotting using the indicated antibodies. The intensity of the bands in the left panel of b was
quantiﬁed and relative HIF-1a protein levels after the siUCHL1-1 or -2 treatment to those after the Scr-siRNA treatment were shown in the right panel of b.
(c,d) HeLa/ODD-Luc (c: left), MCF7/ODD-Luc (c: right), 293T (d: left) and MDA-MB-436 (d: right) were transiently transfected with either pcDNA4/
UCHL1 (UCHL1) or pcDNA4/myc-His A (EV) (c), or treated with either scramble-siRNA (Scr) or UCHL1-siRNA (siUCHL1) (d), cultured under normoxic
(20%) or hypoxic (1%) conditions for 24 h, and then subjected to western blotting using the indicated antibodies and the luciferase assay. (e) HeLa cells
were transiently transfected with pcDNA4/UCHL1 (UCHL1) or pcDNA4/myc-His A (EV), cultured under hypoxic conditions (0.1%) for 24 h, treated
with cycloheximide (10 mgml 1) under normoxic conditions (20%) for the indicated period, and harvested for western blotting with the indicated
antibodies. (f) Western blotting of the HeLa cell lysate after the hypoxic treatment (1%) for the indicated periods with or without the transient transfection
of the UCHL1 expression vector. Mean±s.d. n¼ 3. *Po0.05, **Po0.01, Student’s t-test (b,c) and Dunnett’s test (d).
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was only observed in the presence of VHL (Fig. 3h). Our
results indicated that the aberrant expression of UCHL1 in
cancer cells abrogated the VHL-mediated ubiquitination of
HIF-1a, which led to the stabilization of HIF-1a and subsequent
activation of HIF-1.
UCHL1 promotes distant tumour metastases. We subsequently
investigated the inﬂuence of the UCHL1-mediated activation of
HIF-1 on tumour malignancy. We focused on metastasis as we
already determined that UCHL1 induced the expression of
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and Supplementary Fig. 7). We used a murine model of pul-
monary metastasis, in which a cancer cell suspension was intra-
venously injected into the tail vein of immunodeﬁcient mice, and
the number of resultant metastatic colonies was externally
quantiﬁed in the lungs. To monitor the growth of pulmonary
metastases in real-time, we utilized the stable transfectants of
cancerous EMT6 and B16F10 cells with the pEF-luc plasmid12,
which constitutively expressed ﬁreﬂy luciferase (EMT6/EF-Luc
and B16F10/EF-Luc, respectively). EMT6/EF-Luc cells, which
originally expressed negligible amounts of endogenous UCHL1
(Supplementary Fig. 2), were stably transfected with the UCHL1
expression vector or its empty vector (Fig. 4a). The resultant
clones, EMT6/EF-Luc/UCHL1 and EMT6/EF-Luc/EV cells,
showed that the forced expression of UCHL1 induced the
expression of HIF-1a and HIF-1 activity (Supplementary
Fig. 10a,b) and enhanced cell migration (Supplementary
Fig. 11), but did not promote cell proliferation in vitro, EF-Luc
reporter activity or the growth of tumour xenografts following
subcutaneous transplantation (Supplementary Fig. 10c–e).
Optical imaging after the intravenous transplantation of these
cells in the mouse model of pulmonary metastasis showed that
the overexpression of UCHL1 signiﬁcantly accelerated the
increase in bioluminescent intensity in the lungs (Fig. 4b,c).
The number of metastatic colonies was markedly increased by the
forced expression of UCHL1 (Fig. 4d,e). These results suggested
that UCHL1, possibly through the activation of HIF-1, promoted
the formation of metastatic colonies without accelerating the
proliferation of cancer cells. This conclusion was supported by a
loss-of-function study on the murine model of pulmonary
metastasis using the murine melanoma cell line, B16F10, which
originally showed the higher endogenous expression of UCHL1
(Supplementary Fig. 2). We used B16F10/EF-Luc cells stably
transfected with the plasmid expressing either short-hairpin RNA
(shRNA) for mouse UCHL1 or scramble shRNA (as a negative
control) to establish B16/EF-Luc/shUCHL1 and B16/EF-Luc/
shNC, respectively. Although the silencing of endogenous
UCHL1 (Fig. 4f and Supplementary Fig. 12a,b) did not inhibit
EF-Luc reporter activity or cell proliferation in vitro
(Supplementary Fig. 12c,d), it did inhibit the induction of HIF-
1a expression under hypoxic conditions (Supplementary
Fig. 12b) and eventually suppressed the growth and formation
of pulmonary metastasis (Fig. 4g–j).
We next used a complementary murine model of pulmonary
metastasis, in which the stable transfectants of the murine breast
cancer cells, EMT6, with the UCHL1 expression vector or its
empty vector were transplanted orthotopically into the mammary
fat pad (Fig. 4k–m). Although the overexpression of UCHL1 did
not promote the growth of primary tumour xenografts in the
mammary fat pad (Fig. 4k), the number of metastatic colonies
was markedly increased by the forced expression of UCHL1
(Fig. 4l,m). This result further strengthened the conclusion that
UCHL1 promoted distant tumour metastases.
UCHL1 promotes metastases in a HIF-1-dependent manner.
We used an inhibitor of HIF-1, YC-1, and a plasmid expressing
shRNA for HIF-1a, shHIF-1a, to directly examine the involve-
ment of HIF-1a in the formation of pulmonary metastasis
enhanced by UCHL1. Mice were treated daily with YC-1 from 3
to 5 days after the intravenous transplantation of EMT6/EF-Luc/
EV and EMT6/EF-Luc/UCHL1 cells. The YC-1 treatment sig-
niﬁcantly decreased the UCHL1-dependent increase in biolumi-
nescent intensity and reduced the number of metastatic colonies
in the lungs (Fig. 5a–d). We then performed experiments using
EMT6/EF-Luc/shHIF-1a cells that were stably transfected with
both the UCHL1-expressing vector and HIF-1a-silencing vector
(Supplementary Fig. 13). HIF-1a silencing was conﬁrmed to
suppress the UCHL1-mediated promotion of cell migration in a
Transwell migration assay (Fig. 5e,f). The experimental metastasis
assay conﬁrmed that stable HIF-1a knockdown almost com-
pletely abrogated the UCHL1-mediated increase in the number of
metastatic foci (Fig. 5g,h). These results collectively demonstrated
that the overexpression of UCHL1 promoted distant tumour
metastases in a HIF-1-dependent manner.
Prognostic value of UCHL1 expression level in human cancer.
To validate our results in human tumours, we ﬁrst performed
an immunohistochemical analysis on human breast cancers
using anti-UCHL1 and anti-HIF-1a antibodies (Fig. 6a,b and
Supplementary Figs 14,15). Tumour samples were categorized
into three groups (high, intermediate and low) according to the
expression levels of UCHL1 and HIF-1a, respectively. We con-
ﬁrmed that the expression levels of UCHL1 positively correlated
with those of HIF-1a (Table 1; R2¼ 0.534). We then analysed the
relationship between UCHL1 expression levels and poor prog-
nosis using the PrognoScan database. We conﬁrmed that the
expression levels of UCHL1 positively correlated with lower
overall survival and distant metastasis-free survival rates in
human breast cancer, lung cancer and melanoma (Fig. 6c and
Supplementary Fig. 16). We next performed the same type of
analyses on tissue microarrays mounted with human lung
cancers17,18. Tumour samples were categorized into four groups
Figure 3 | UCHL1 functions as a deubiquitinating enzyme for HIF-1a. (a,b) HeLa/5HRE-Luc (a) and HeLa/ODD-Luc (b) cells were transiently transfected
with pcDNA4/UCHL1 (UCHL1), pcDNA4/UCHL1 C90S (UCHL1 C90S) or pcDNA4/myc-His A (EV), cultured under normoxic (20%) or hypoxic (1%)
conditions for 24 h, and subjected to western blotting using the indicated antibodies and luciferase assay. (c,d) 293Tcells transiently transfected with both
pcDNA4A/HIF-1a-myc and pMT132 were treated with either scramble-siRNA (Scr) or UCHL1-siRNA (siUCHL1) (c) or additionally transfected with
pcDNA4/myc-His A (EV) or pcDNA4/UCHL1 (UCHL1) (d), and cultured with MG132 (30mgml 1) for 6 h. Ubiquitinated HIF-1a was immunoprecipitated
using an anti-HIF-1a antibody and detected with an anti-ubiquitin antibody (left). One-ﬁftieth of the whole cell lysate (WCL) was subjected to western
blotting with the indicated antibodies (right). (e) Twenty-four hours after the transient transfection with the expression vector for HIF-1a (pcDNA4A/HIF-
1a) and either the expression vector for UCHL1 (pcDNA4/UCHL1) or its empty vector, cells were precultured under normoxic (20%) or hypoxic (1%)
conditions for 24 h, treated with MG132 (30mM) under the same oxygen conditions as the preculture, and subjected to immunoprecipitation with the anti-
UCHL1 antibody and subsequent western blotting with the indicated antibodies. Paraformaldehyde solution (1%) was used as a cross-linking reagent. One-
ﬁftieth of the WCL was subjected to western blotting with the indicated antibodies. (f) Twenty-four hours after the transient transfection with the
expression vectors for HIF-1a (pcDNA4/HIF-1a), VHL-myc (pEF6/VHL-myc), UCHL1 (pcDNA4/UCHL1) or their empty vector, cells were treated with
MG132 (30mgml 1) for an additional 6 h. VHL-myc was immunoprecipitated using an anti-myc antibody and co-precipitated HIF-1a was detected. One-
ﬁftieth of the WCL was subjected to western blotting with the indicated antibodies (lower). (g,h) RCC4 plus vector alone and RCC4 plus VHL cells were
transiently transfected with p5HREp-luc and either pcDNA4/UCHL1 (UCHL1) or pcDNA4/myc-His A (EV), cultured under normoxic (20%) or hypoxic
(0.1%) conditions for 24 h, and subjected to western blotting using the indicated antibodies and luciferase assay. Mean±s.d. n¼ 3. *Po0.05; NS, not
signiﬁcant, Student’s t-test (g) and Dunnett’s test (a,b). IP, immunoprecipitation; IB, immunoblot; WB, western blotting.
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(þ þ þ , þ þ , þ ,  ) according to the expression levels of
UCHL1 and HIF-1a, respectively. The expression levels of
UCHL1 correlated well with those of HIF-1a in lung tumours
(Fig. 6d,e and Table 2). Moreover, high expression levels of both
UCHL1 and HIF-1a (þ þ þ and þ þ ) were strongly
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Figure 4 | UCHL1 promotes distant tumour metastases. (a) Two clones of the EMT6/EF-Luc/EV and EMT6/EF-Luc/UCHL1 cells were subjected to
western blotting with the indicated antibodies. (b–e) The growth of pulmonary metastases was monitored by in vivo imaging as luciferase bioluminescence
on the indicated days after the intravenous transplantation of EMT6/EF-Luc/EV (EV) and EMT6/EF-Luc/UCHL1 (UCHL1) cells (b). (c) Representative
images. (d) The relative number of metastatic lung colonies in the UCHL1 group to that in the EV group was analysed 10 days after transplantation.
(e) Representative images. n¼ 12. (f–j) By using two clones of B16F10/EF-Luc/shNC and B16F10/EF-Luc/shUCHL1 (shRNA version A and B) cells (f), the
same experiments as those described in a to e were performed. (k–m) EMT6/EF-Luc/EV (EV) and EMT6/EF-Luc/UCHL1 (UCHL1) cells were
orthotopically transplanted to the fat pads of female scid mice. The growth of primary tumours (k) and relative number of metastatic lung colonies
in the UCHL1 group to that in the EV group was analysed 27 days after transplantation (l). n¼6. (m) Representative images. Mean±s.d. *Po0.05,
**Po0.01, Student’s t-test (b,d,g,i,k,l). NS, not signiﬁcant.
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(Fig. 6f,g). These results suggested that the expression of UCHL1
would lead to a poor prognosis by activating HIF-1; therefore, it
could be a useful prognostic marker.
We used the small-molecule UCHL1 inhibitor, LDN57444, to
establish whether UCHL1 could be exploited as a therapeutic
target to reduce the incidence of distant tumour metastases. Using
the 5HREp-luc reporter gene in vitro, we conﬁrmed that
LDN57444 signiﬁcantly inhibited HIF-1 activity in the presence
of endogenous UCHL1 expression in 293T cells (Fig. 7a);
however, it had no effect on HIF-1 activity in HeLa cells because
of the absence of endogenous UCHL1 (Fig. 7b). The reconstitu-
tion of UCHL1 in HeLa cells restored the HIF-1-blocking activity
of the drug (Fig. 7c). The in vivo murine model of pulmonary
metastasis also demonstrated that LDN57444 did not inhibit
metastatic tumour formation when the endogenous expression of
UCHL1 was low (Fig. 7d,e, EV), but did when UCHL1 was
reconstituted (Fig. 7d,e, UCHL1). The number of metastatic
colonies 10 days after the intravenous transplantation of EMT6/
EF-Luc/EV and EMT6/EF-Luc/UCHL1 cells also revealed that
LDN57444 had an antimetastatic effect on UCHL1-expressing
cancer cells (Fig. 7f,g). LDN57444 was not less effective than YC-
1 in inhibiting pulmonary metastasis (Fig. 7h–k). Although
UCHL1 was previously reported to be expressed in neurons, testis
and ovary, we did not observe any obvious side effects after the
administration of LDN57444, such as reductions in body weights
or behavioural disorders, at least in our experimental setting
(Supplementary Figs 17 and 18a). Furthermore, the administra-
tion of LDN57444 to both male and female mice during their
mating was not conﬁrmed to cause a decrease in the body weights
of neonatal mice (Supplementary Fig. 18b). Taken together, these
results indicated that UCHL1 is a good therapeutic target for the
suppression of distant tumour metastases.
Discussion
In the present study, we provided a novel insight into the
regulatory mechanism underlying tumour metastasis via activa-























































































































































Figure 5 | UCHL1-mediated promotion of distant tumour metastases are HIF-1 dependent. (a–d) Mice were treated with (þ ) or without ( ) the HIF-1
inhibitor, YC-1 (30mg kg 1 daily) between 3 and 5 days after the intravenous transplantation of EMT6/EF-Luc/EV (EV) and EMT6/EF-Luc/UCHL1
(UCHL1) cells. (a) The total volume of pulmonary metastases was monitored by in vivo imaging as luciferase bioluminescence 7 days after transplantation.
n¼4. (b) Representative images. (c) Relative number of metastatic lung colonies to the EV and YC-1 ( ) group. n¼4. (d) Representative images.
(e,f) A Transwell migration assay using EMT6/EF-Luc/shNC/EV (upper left in the right panels in e and f), EMT6/EF-Luc/shHIF-1a/EV (upper right),
EMT6/EF-Luc/shNC/UCHL1 (lower left) and EMT6/EF-Luc/shHIF-1a/UCHL1 (lower right) cells under normoxic (20%, e) and hypoxia (1%, f) conditions.
Mean±s.d. n¼4, *Po0.05. Representative images are shown on the right. (g,h) By using two clones of EMT6/EF-Luc/shNC/EV, EMT6/EF-Luc/shHIF-
1a/EV, EMT6/EF-Luc/shNC/UCHL1 and EMT6/EF-Luc/shHIF-1a/UCHL1 cells, the same experiments as those described in Fig. 4d,e were performed.
(g) Relative number of metastatic lung colonies to the EV and shNC group. n¼ 12. Mean±s.d. *Po0.05, **Po0.01; NS, not signiﬁcant, Student’s
t-test (a,c,e,f,g).
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that HIF-1 functions in multiple steps of distant tumour
metastasis3,7, for example, in the acquisition of an invasive
phenotype of cancer cells through the so-called epithelial-to-
mesenchymal transition, local invasion to blood vessels by
degrading the extracellular matrix, formation of a premetastatic
niche in distant organs, extravasation by degrading the
extracellular matrix and adaptation to the microenvironments
of distant tissues3,19. UCHL1 has also been shown to be a key
regulator of the invasion and metastasis of cancer cells20;
however, its downstream factors have yet to be characterized.
Under these conditions, one of the most signiﬁcant advancements
of this study is the mechanistic and functional link detected
between UCHL1 and HIF-1 in distant tumour metastasis. This
result as well as recent clinical ﬁndings, in which the expression
levels of HIF-1a and UCHL1 correlated with the tumour
stage, grading and overall survival of breast cancer patients4,5,21,
offers a rational basis for targeting the UCHL1–HIF-1 axis
(deubiquitination of HIF-1a) to control cancer metastases.
In the present study, we provided direct evidence to show that
UCHL1 was responsible for the deubiquitination of HIF-1a and
upregulated HIF-1 activity. To date, UCHL1 has been reported to
exhibit ubiquitin hydrolase activity22; however, the inﬂuence of
UCHL1 on HIF-1a has not yet been elucidated. The factors
reported as the downstream substrates of UCHL1 were the pro-
apoptotic gene, NOXA, and the mediator of Wnt signalling, b-
catenin23,24; on the other hand, the gene that was shown to
deubiquitinate HIF-1a was pVHL-interacting deubiquitinating
enzyme 2 (VDU2)25. Although the detailed mechanisms
responsible for the actions of and relationship between UCHL1
and VDU2 remain unclear, this study emphasized the importance
of the deubiquitination of HIF-1a, in addition to the increase in
the stability and transactivation activity of HIF-1a, in the positive
regulation of HIF-1 activity. To fully elucidate the physiological
and pathophysiological importance of deubiquitination, it is
critical to more thoroughly analyse the meaning of our
immunoprecipitation data in which UCHL1 bound to HIF-1a
high (+++)
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Figure 6 | UCHL1 is a good prognostic marker. (a–c) Human breast tumour sections (30 samples) were stained with anti-UCHL1 (a) and anti-HIF-1a (b)
antibodies (scale bar, 50mm). (c) A PrognoScan database-based Kaplan–Meier analysis of the overall survival of 158 breast cancer patients stratiﬁed by
high (red) and low (blue) UCHL1 levels (high: n¼ 23, low: n¼ 135; log-rank tests Po0.05). (d–g) Microarrays spotted with human lung tumour tissues
(254 samples) were stained with anti-UCHL1 (d) and anti-HIF-1a (e) antibodies (scale bar, 500mm). A Kaplan–Meier analysis of the overall survival of the
254 lung cancer patients stratiﬁed by high (red; þ þ þ and þ þ in d,e) and low (blue;þ and  in d,e) UCHL1 (f) and HIF-1a (g) levels (log-rank tests,
Po0.05).
Table 1 | The relationship between HIF-1a and UCHL1
expression levels in human breast cancers.
HIF-1a levels
Low (þ ) Intermediate
(þ þ )
High
(þ þ þ )
UCHL1 levels
Low (þ ) 4 (13%) 0 (0%) 0 (0%)
Intermediate (þ þ ) 2 (7%) 7 (23%) 5 (17%)
High (þ þ þ ) 0 (0%) 3 (10%) 9 (30%)
The relationship between HIF-1a and UCHL1 expression levels was analysed in human breast
cancers.
Table 2 | The relationship between HIF-1a and UCHL1
expression levels in human lung cancers.
HIF-1a levels
Low
( and þ )
High
(þ þ and þ þ þ )
UCHL1 levels
Low ( and þ ) 94 (37%) 117 (46%)
High (þ þ and þ þ þ ) 3 (1%) 40 (16%)
The relationship between HIF-1a and UCHL1 expression levels was analysed in human lung
cancers (w2 test, Po0.0001).
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and prevented VHL from directly interacting with HIF-1a
(Fig. 3e,f) and the interaction between UCHL1 and HIF-1a was
facilitated under hypoxic conditions (Fig. 3e).
The importance of UCHL1 in the stabilization of HIF-1a and
resultant activation of HIF-1 was also validated in clinical human
tumours; the expression levels of UCHL1 correlated well with
those of HIF-1a in both breast and lung cancers. However, the
inﬂuence of UCHL1 on HIF-1a expression observed in the
present study appeared to be greater in clinical tumour tissues
than in cancer cells cultured under simple low-oxygen conditions.
Although the reason for this difference is currently unclear, one
possibility is that tumour-speciﬁc microenvironments other than
simple hypoxia, such as a decrease in the availability of glucose as
well as oxygen, may be important for the activity of the UCHL1–
HIF-1 axis based on the results of our in vitro experiment; the
impact of UCHL1 on HIF-1a stability was facilitated when
glucose concentrations decreased under hypoxic conditions
(Supplementary Fig. 19).
We conﬁrmed that UCHL1 expression levels in malignant
tumours correlated with the poor prognosis of patients with
breast and lung cancers. This result was consistent with the
ﬁndings of previous studies in which UCHL1 was shown to be
involved in tumour metastases20,26 and closely associated with
the advanced stages of lung cancer as well as with the
tumorigenesis, progression and invasiveness of cancers27–29.
These ﬁndings have justiﬁed exploiting UCHL1 as a prognostic
marker and treatment target for cancers. However, in order to
realize diagnostic and therapeutic strategies, it is critical to
approach the following issues: (i) the inﬂuence of UCHL1 not
only on HIF-1a, but also on HIF-2a, (ii) the factors required for
the recognition of downstream substrates by UCHL1 and (iii) the
expression levels of UCHL1 in normal tissues. Furthermore, as
epigenetic alterations have been suggested to be important for
regulating the expression and functions of UCHL1 (refs 30–33), it
is also important to analyse their meaning and underlying























































































































































































































50 kDa+ – + – + – + α-β-Actin Abβ-Actin 3 5 7
UCHL1
UCHL1
LDN57444YC-1 Control LDN57444YC-1 Control LDN57444YC-1
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Figure 7 | UCHL1 is a good therapeutic target. (a–c) 293T cells transiently transfected with the 5HREp-luc reporter gene (a) and HeLa/5HRE-Luc cells
(b,c) with none (b) or either pcDNA4/UCHL1 (UCHL1) or pcDNA4/myc-His A (EV) (c) were treated with (þ ) or without ( ) the UCHL1 inhibitor,
LDN57444, cultured under normoxic or hypoxic conditions for 24 h, and subjected to western blotting using the indicated antibodies and luciferase assay.
n¼ 3. (d–g) Athymic nude mice were intravenously transplanted with EMT6/EF-Luc/EV or EMT6/EF-Luc/UCHL1 cells, and treated with or without
LDN57444 (0.5mg kg 1 daily) from 3 to 5 days after the transplantation. (d,e) On the indicated days after transplantation, mice were subjected to an
optical in vivo imaging experiment. n¼ 6. (f,g) The relative number of metastatic colonies to the EV and LDN57444 group was analysed in the lungs 10 days
after transplantation. n¼ 6. (h–k) Athymic nude mice were transplanted with B16F10/EF-Luc cells through the tail vein, and treated with or without YC-1
(30mg kg 1 daily) or LDN57444 (0.5mg kg 1 daily) from 3 to 5 days after transplantation. (h,i) Mice were subjected to an optical in vivo imaging
experiment 7 days after transplantation. n¼ 9. (j,k) The relative number of metastatic colonies to the control group was analysed in the lungs 10 days after
transplantation. n¼9. Mean±s.d. *Po0.05; NS, not signiﬁcant, Student’s t-test (a–d,f,h,j).
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systemic administration of UCHL1 inhibitors also need to be
examined and drug delivery systems have to be developed for
these inhibitors as UCHL1 expression has been conﬁrmed to
some extent in neurons, the testis and ovary. Solutions to these
issues should lead to the development of novel antimetastatic
strategies in the future.
Methods
Cell culture and reagents. NIH/3T3, HeLa, MCF7, MDA-MB-231, MDA-MB-
436, DU 145, 293T, EMT6 and B16F10 were purchased from the American Type
Culture Collection. RCC4 plus vector alone and RCC4 plus VHL, which are human
renal cell carcinoma cell lines (RCC4) stably transfected with pcDNA3 (empty
vector) and pcDNA3-VHL (VHL-expressing vector), were purchased from DS
Pharma Biomedical. Cells were maintained in 10% FBS-Dulbecco’s modiﬁed
Eagle’s medium. Cells were incubated in a well-humidiﬁed incubator with 5% CO2
and 95% air for the normoxic incubation or in the Bactron Anaerobic Chamber,
BACTLITE-2 (Sheldon Manufacturing) and in a RUSKIN INVIVO2 500 (Ruskinn)
for the hypoxic incubation ato0.1% O2 and 1% O2, respectively. Stock solutions of
cycloheximide (Nacalai Tesque) and LDN57444 (Merck) were prepared in dime-
thylsulphoxide (10mgml 1 and 10mM, respectively). Double-stranded RNAs for
the transient silencing of UCHL1 (silencer Select Validated siRNA, Cat# 4390824-
s14616: 50-AAGUUAGUCCUAAAGUGUATT-30, 4390824-s14617: 50-GCACAA
UCGGACUUAUUCATT-30, 4390824-s14618: 50-GACCAUUGGGAAUUCCUG
UTT-30) and for the negative control (Cat# 12935-300: sequence information is not
disclosed) were purchased from Life Technologies.
Plasmid constructs. To construct pcDNA4/UCHL1, the cDNA encoding human
uchl1 gene was ampliﬁed from the cDNA of HeLa cells and inserted between the
EcoRV and XhoI sites of pcDNA4/myc-His A (Invitrogen). To construct pcDNA4/
UCHL1 C90S, the C90S mutation was introduced into pcDNA4/UCHL1 using
PCR-based site-directed mutagenesis with the following primers; 50-AATTCCTC
TGGCACAATCGGACTTATTC-30 and 50-CGATTGTGCCAGAGGAATTCCC
AATGG-30 . To construct p5HRE-BSD, the luciferase coding sequence between the
NcoI and XbaI sites of p5HRE-Luc12 was substituted for the bsd-coding fragment.
To construct pEF/SV40p-ODD-Luc, the DNA fragment encoding the SV40p-ODD-
luc reporter gene was prepared by digesting pGL3/ODD-Luc with KpnI and XbaI,
and inserted between the corresponding sites of pEF/myc/cyto (Invitrogen). The
plasmids, pEF-Luc and p5HRE-Luc, were constructed as described previously12.
The haemagglutinin (HA)-tagged ubiquitin expression plasmid, pMT123, was
described previously34. To construct the plasmid pcDNA4/HIF-1a-myc and
pcDNA4/HIF-1a, the coding sequence of the HIF-1a gene was ampliﬁed by PCR
from the human cDNA library and inserted between the BamHI and EcoRV sites of
pcDNA4/myc-His B and pcDNA4/myc-His A (Invitrogen), respectively. To
construct pEF6/VHL-myc, the cDNA encoding the human vhl gene was inserted
between the EcoRI and XbaI sites of pEF6/myc-His A (Invitrogen). Plasmids
expressing shRNA for mouse UCHL1 (Cat# 336314 KM27639P, clone A insert
sequence: 50-CGAAGATAGAGCCAAGTGTTT-30 and clone B insert sequence:
50-TGAAGCAGACCATCGGAAACT-30), for human HIF-1a (Cat# 336314
KM03799P, clone A insert sequence: 50-ATAGCGATATGGTCAATGTAT-30 and
clone B insert sequence: 50-CGAGTGAAAGGATTCATATCT-30) and for the
negative control (Cat# 336314 KM27639P, NC insert sequence: 50-GGAATCTC
ATTCGATGCATAC-30) were purchased from QIAGEN.
Stable transfectants. NIH3T3, HeLa, MCF7, MDA-MB-231, EMT6 or B16F10
cells were stably transfected using the calcium phosphate method35 with p5HRE-
BSD (for NIH3T3/5HRE-BSD), pEF/SV40p-ODD-Luc (for HeLa/ODD-Luc and
MCF7/ODD-Luc), p5HRE-Luc (for HeLa/5HRE-Luc, MCF7/5HRE-Luc, MDA-
MB-231/5HRE-Luc, EMT6/5HRE-Luc and B16F10/5HRE-Luc), pEF-Luc (for
EMT6/EF-Luc and B16F10/EF-Luc), the combination of pEF-Luc and either
pcDNA4/myc-His A (Invitrogen; for EMT6/EF-Luc/EV (clone #1, 2)) or pcDNA4/
UCHL1 (for EMT6/EF-Luc/UCHL1 (clone #1, 2)), the combination of pEF-Luc
and the plasmid expressing either shRNA for mouse UCHL1 (QIAGEN; 336314
KM27639P; for B16F10/EF-Luc/shUCHL1 (clone #A1, A2, B1 and B2)) or the
negative control (QIAGEN; 336314 KM27639P; for B16F10/EF-Luc/shNC (clone
#1, 2)), or the combination of pEF-Luc and either the plasmid expressing either
shRNA for mouse HIF-1a (QIAGEN; 336314 KM03799P; for EMT6/EF-Luc/
shHIF-1a (clone #1, 2)) or the negative control (QIAGEN; 336314 KM03799P; for
EMT6/EF-Luc/shNC (clone #1, 2)). EMT6/EF-Luc/shHIF-1a cells were stably
transfected with either pcDNA4/myc-His A (for EMT6/EF-Luc/shHIF-1a/EV
(clone #1, 2)) or pcDNA4/UCHL1 (for EMT6/EF-Luc/shHIF-1a/UCHL1 (clone
#1, 2)). EMT6/EF-Luc/shNC cells were stably transfected with either pcDNA4/
myc-His A (for EMT6/EF-Luc/shNC/EV (clone #1, 2)) or pcDNA4/UCHL1 (for
EMT6/EF-Luc/shNC/UCHL1 (clone #1, 2)). Cells were cultured for 12–14 days in
culture medium containing the corresponding antibiotic to select antibiotic-
resistant stable transfectants. The resultant colonies were isolated and established as
clones. Representative clones showing the expected and reasonable activities were
used in the present study.
Screening of upstream activators of HIF-1. EcoPack2-293 cells (BD Bioscience;
2 106 cells per f100mm dish), which were HEK-293-based packaging cells, were
transiently transfected with 20 mg of the plasmid encoding the human placenta
cDNA library (Clontech) for retrovirus production. NIH3T3/5HRE-BSD cells were
infected with the resultant retroviruses, and cultured in the presence of 5 mgml 1
blasticidin S under normoxic conditions for 10 days. DNA fragments encoding the
potential activators of HIF-1 were rescued by PCR using 50 and 30 LIB primers
(Clontech) from the genomic DNA of surviving colonies and then subjected to the
sequencing analysis.
Luciferase assay and western blotting. Twenty-four hours after cells (1 104
cells per well in a 24-well plate for the luciferase assay and 2 105 cells per well in a
6-well plate for western blotting) were transfected with the indicated plasmids, they
were treated under normoxic (20% O2) and hypoxic (0.1 or 1% O2) conditions for
the indicated periods, and harvested in 100 ml Passive Lysis Buffer (Promega) for
the luciferase assay or 150ml Cell Lytic Buffer (Sigma-Aldrich) for western blotting.
The luciferase assay was performed using the dual luciferase assay kit according to
the manufacturer’s instructions (Promega). The plasmid, pRL-SV40 (Promega),
was used as an internal control to calculate relative luciferase activity. Western
blotting was performed using anti-HIF-1a (500-fold dilution, BD Bioscience for
human HIF-1a; 500 times dilution, Novus Biologicals for mouse HIF-1a), anti-
UCHL1 (500-fold dilution, Sigma-Aldrich), anti-myc epitope tag (1,000-fold
dilution, Cell Signaling) and anti-b-actin (500-fold dilution, BioVision) antibodies
as the primary antibodies, anti-mouse and anti-rabbit IgG horseradish peroxidase-
linked whole antibodies (5,000-fold dilution; GE Healthcare) as the secondary
antibodies, and the ECL Plus Western Blotting Detection system (GE Healthcare)
for detection according to the manufacturer’s instructions. Images of bands were
acquired using a digital photo scanner GT-X750 (Seiko Epson Corp) and quanti-
ﬁed using ImageJ as described previously36. Images have been cropped for
presentation. Full size images are presented in Supplementary Fig. 20.
qRT–PCR. Twenty-four hours after cells (2 105 cells per well in a 6-well plate)
were transfected with the indicated plasmids, total RNA was extracted using
Sepasol RNA I Super according to the manufacturer’s instructions (Nacalai Tes-
que). Total RNA (1mg) was subjected to reverse transcription using RNA LA PCR
Kit (AMV) version 1.1 (Takara Bio). The mRNA levels of the indicated genes were
quantiﬁed using the qRT–PCR technique with the Thermal Cycler Dice Real Time
System (TP-800; Takara Bio) with the SYBR Premix Ex Taq kit (Takara Bio) and
primers (Takara Primer Set ID HA160790 for VEGFA mRNA, HA126121 for
GLUT1 mRNA, HA173965 for MMP2 mRNA, HA129244 for MMP9 mRNA,
HA162299 for human UCHL1 mRNA, MA116539 for mouse UCHL1 mRNA,
HA067803 for human b-actin mRNA and MA050368 for mouse b-actin mRNA)
according to the manufacturer’s instructions. b-Actin mRNA levels were used as a
normalizer.
Immunoprecipitation assay. Twenty-four hours after cells (1.6 106 cells per
100mm dish) were transfected with the indicated plasmids and/or with the indi-
cated siRNA, they were harvested in 1,000 ml Cell Lytic Buffer (Sigma-Aldrich), and
immunoprecipitated using the Immunoprecipitation Kit Dynabeads Protein G
(Life Technologies) with the indicated antibody according to the manufacturer’s
instructions. Western blotting was performed using the indicated antibody.
Transwell migration assay. Cells were seeded to insert wells of the Transwell
chamber (5 104 cells per an insert well; Corning, 8-mm pore, 24-well plate for-
mat), pre-treated with serum-starved DMEM medium for 24 h and cultured under
normoxic (20% O2 for 24 h) or hypoxic (1% O2 for 12 h) conditions in DMEM
medium supplemented with and without FBS in bottom wells and upper insert
wells, respectively, according to the manufacturer’s instructions. Migrating cells
were stained with Giemsa solution.
In vivo experiments. Cancer cell suspensions were transplanted into the tail
veins of athymic nude mice (BALB/c nu/nu; Japan SLC Inc., 3 104 cells per
mouse) or into the mammary fat pads of scid mice (C.B-17/Icr-scid/scid Jcl,
CLEA Japan, Inc., 1 105 cells per mouse) for a mouse model of pulmonary
metastasis after intravenous or orthotopic transplantation, respectively. Optical
in vivo imaging was performed with IVIS-SPECTRUM (Caliper)12,37.
Bioluminescent images were acquired 10min after the intraperitoneal injection
of the luciferin solution (100 ml of 10mgml 1 solution). Mice were anaesthetised
with 2.5% isoﬂurane gas in the oxygen ﬂow (1.5mlmin 1) during imaging.
The signal intensity was quantiﬁed and analysed using Living Image 2.50-Igor
Pro 4.90 software (Caliper).
Immunohistochemical analysis. Formalin-ﬁxed and parafﬁn-embedded sections
of human breast tumours were subjected to immunohistochemical staining using
the DAKO LSABþ System-HRP kit (DAKO) with anti-UCHL1 (Sigma-Ardrich)
and anti-HIF-1a (Novus Biologicals) antibodies as the primary antibodies,
according to the manufacturer’s instructions.
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Prognoscan analysis. The relationship between UCHL1 expression levels
and overall survival and distant metastasis-free survival rates was evaluated in
cancer patients by the minimum P-value approach using the PrognoScan
database38. Brieﬂy, patients were divided into two groups according to UCHL1
expression levels in their tumours at all possible cutoff points. The risk differences
of any two groups were then calculated by the log-rank test. The cutoff point
giving the most signiﬁcant P-value was selected and demonstrated in the present
study.
Ethics of research using animals and clinical samples. All animal experiments
using BALB/c nu/nu (9-week-old, female, Japan SLC Inc.), BALB/c (10-week-old,
male and female, Japan SLC Inc.) and C.B-17/Icr-scid/scid Jcl (9-week-old, female,
CLEA Japan, Inc.) were approved by the Animal Research Committee of Kyoto
University, and performed according to the guidelines governing animal care in
Japan. The study protocols using human breast and lung cancer samples were
approved by the Ethics Committee of Kyoto University Hospital. Informed consent
was obtained from all patients. The study was performed in accordance with the
Helsinki Declaration. Preparations of tissue microarrays mounted with human
lung tumours were described previously17,18.
Statistical analyses. The signiﬁcance of differences between two independent
subjects and among multiple subjects was determined using the Student’s t-test and
Dunnett’s test, respectively. The Kaplan–Meier method was used to evaluate
patients’ prognoses and log-rank tests were used to compare survival rates among
groups. A P-value o0.05 was considered to be signiﬁcant.
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